Korro Bio (KRRO) reported second-quarter 2026 results and said KRRO-121 remains on track to begin a first-in-human clinical trial in the second half of 2026. The company ended the quarter with $137.9 million in cash, cash equivalents and marketable securities, which it said provides runway into the second half of 2028.
Korro reported no collaboration revenue for the quarter, compared with $1.5 million a year earlier. Net loss was $18.9 million, compared with $25.8 million in the second quarter of 2025.
- Cash, cash equivalents and marketable securities were $137.9 million as of June 30, 2026.
- KRRO-121 received Orphan Drug Designation from the European Medicines Agency for patients with urea cycle disorders.
- Korro nominated KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency.
- R&D expenses were $13.6 million, down from $20.1 million a year earlier.
- G&A expenses were $6.5 million, down from $7.3 million a year earlier.
- Net loss per share, basic and diluted, was $1.07.
$KRRO Insider Trading Activity
$KRRO insiders have traded $KRRO stock on the open market 30 times in the past 6 months. Of those trades, 10 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $KRRO stock by insiders over the last 6 months:
- JEAN FRANCOIS FORMELA has made 0 purchases and 14 sales selling 284,288 shares for an estimated $4,041,449.
- SCOTT D SANDELL purchased 207,100 shares for an estimated $2,300,881
- FOREST BASKETT purchased 207,100 shares for an estimated $2,300,881
- EDWARD T MATHERS purchased 207,100 shares for an estimated $2,300,881
- PAUL EDWARD WALKER purchased 207,100 shares for an estimated $2,300,881
- ANTHONY A. JR. FLORENCE purchased 207,100 shares for an estimated $2,300,881
- MOHAMAD MAKHZOUMI purchased 207,100 shares for an estimated $2,300,881
- CARMEN CHANG purchased 207,100 shares for an estimated $2,300,881
- ENTERPRISE ASSOCIATES 17, L.P. NEW purchased 207,100 shares for an estimated $2,300,881
- RICK YANG purchased 207,100 shares for an estimated $2,300,881
- RAM AIYAR (President and CEO) has made 0 purchases and 2 sales selling 20,954 shares for an estimated $259,589.
- JEFFREY CERIO (General Counsel) sold 6,609 shares for an estimated $71,575
- LOIC A VINCENT (Chief Scientific Officer) sold 3,418 shares for an estimated $37,016
- OLIVER DOLAN (Senior Vice President, Finance) sold 3,383 shares for an estimated $36,637
- TODD CHAPPELL (Chief Operating Officer) sold 3,168 shares for an estimated $34,309
- CAPITAL MANAGEMENT LP LYNX1 purchased 520 shares for an estimated $5,512
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$KRRO Hedge Fund Activity
We have seen 57 institutional investors add shares of $KRRO stock to their portfolio, and 32 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BALYASNY ASSET MANAGEMENT L.P. added 1,040,054 shares (+inf%) to their portfolio in Q1 2026, for an estimated $11,773,411
- LYNX1 CAPITAL MANAGEMENT LP added 860,381 shares (+126.9%) to their portfolio in Q1 2026, for an estimated $9,739,512
- AFFINITY ASSET ADVISORS, LLC added 706,904 shares (+inf%) to their portfolio in Q1 2026, for an estimated $8,002,153
- ADAR1 CAPITAL MANAGEMENT, LLC added 540,054 shares (+inf%) to their portfolio in Q1 2026, for an estimated $6,113,411
- DRIEHAUS CAPITAL MANAGEMENT LLC added 450,045 shares (+inf%) to their portfolio in Q1 2026, for an estimated $5,094,509
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 228,400 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,585,488
- AQR CAPITAL MANAGEMENT LLC added 227,108 shares (+558.7%) to their portfolio in Q1 2026, for an estimated $2,570,862
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
